Given the increasing prevalence of prostate cancer in aging populations, prospective studies specifically designed to assess the efficacy, safety, and quality-of-life impact of PSMA-RLT in elderly and comorbid patient populations are important. This evidence concerns the gene FOLH1 and Familial prostate cancer.